MX2019014265A - Tratamientos conjuntos triples con anticuerpos. - Google Patents
Tratamientos conjuntos triples con anticuerpos.Info
- Publication number
- MX2019014265A MX2019014265A MX2019014265A MX2019014265A MX2019014265A MX 2019014265 A MX2019014265 A MX 2019014265A MX 2019014265 A MX2019014265 A MX 2019014265A MX 2019014265 A MX2019014265 A MX 2019014265A MX 2019014265 A MX2019014265 A MX 2019014265A
- Authority
- MX
- Mexico
- Prior art keywords
- triple combination
- antibody therapies
- combination antibody
- antibodies
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a tratamientos conjuntos triples con anticuerpos anti-TIGIT, anticuerpos anti-PVRIG e inhibidores de punto de control, que incluyen anti-PD-1 o anti-PD-L1.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762513960P | 2017-06-01 | 2017-06-01 | |
US201762515452P | 2017-06-05 | 2017-06-05 | |
US201762538563P | 2017-07-28 | 2017-07-28 | |
US201762547051P | 2017-08-17 | 2017-08-17 | |
US201762582756P | 2017-11-07 | 2017-11-07 | |
US201862618005P | 2018-01-16 | 2018-01-16 | |
PCT/IB2018/000696 WO2018220446A1 (en) | 2017-06-01 | 2018-06-01 | Triple combination antibody therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014265A true MX2019014265A (es) | 2020-08-03 |
Family
ID=63080202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014265A MX2019014265A (es) | 2017-06-01 | 2018-06-01 | Tratamientos conjuntos triples con anticuerpos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11225523B2 (es) |
EP (1) | EP3630180A1 (es) |
JP (2) | JP7348072B2 (es) |
KR (1) | KR20200021474A (es) |
CN (1) | CN110799213A (es) |
AU (1) | AU2018276140A1 (es) |
BR (1) | BR112019025035A2 (es) |
CA (1) | CA3064331A1 (es) |
CL (1) | CL2019003509A1 (es) |
IL (1) | IL271011A (es) |
MX (1) | MX2019014265A (es) |
SG (1) | SG10202111336RA (es) |
WO (1) | WO2018220446A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3347379T5 (da) * | 2016-08-17 | 2020-06-15 | Compugen Ltd | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf |
MX2019006072A (es) * | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
AU2018282094A1 (en) | 2017-06-05 | 2019-12-12 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
AU2019276578A1 (en) * | 2018-06-01 | 2021-01-14 | Compugen Ltd | Anti-PVRIG/anti-TIGIT bispecific antibodies and methods of use |
TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥(蘇州)有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
US11124572B2 (en) * | 2019-04-18 | 2021-09-21 | Qlsf Biotherapeutics Inc. | Humanized anti-PD-L1 antibodies |
AU2020298324A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
WO2021097294A1 (en) * | 2019-11-15 | 2021-05-20 | Surface Oncology, Inc. | Compositions and methods for immunotherapy |
EP4119162A4 (en) * | 2020-03-13 | 2023-08-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PVRIG-BINDING PROTEIN AND ITS MEDICAL USES |
CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
JP7240512B2 (ja) * | 2020-05-26 | 2023-03-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021263115A1 (en) * | 2020-06-26 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
US20230365680A1 (en) * | 2020-09-30 | 2023-11-16 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
EP4284516A1 (en) * | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
US20240076373A1 (en) * | 2021-01-28 | 2024-03-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
WO2023040945A1 (zh) | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | 特异性结合pd-1的蛋白及其医药用途 |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023063842A1 (ru) * | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок |
WO2023064958A1 (en) * | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
WO2023137161A1 (en) * | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024026496A1 (en) * | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US20040002117A1 (en) | 1998-02-12 | 2004-01-01 | Hogan Patrick G. | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
CA2363684A1 (en) | 1999-03-05 | 2000-09-08 | Incyte Pharmaceuticals, Inc. | Human secretory proteins |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US20030224379A1 (en) | 2000-01-21 | 2003-12-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
JP2004536585A (ja) | 2001-05-09 | 2004-12-09 | エール・ユニバーシティ | トル/インターロイキン−1受容体アダプタータンパク質(tirap) |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
US20070224201A1 (en) | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003290432A1 (en) | 2002-12-26 | 2004-07-22 | Asahi Kasei Pharma Corporation | T cell activating gene |
RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005035727A2 (en) | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7622265B2 (en) | 2005-02-22 | 2009-11-24 | Genentech, Inc. | Methods and compositions for modulating prostasin |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
ES2772674T3 (es) | 2005-05-12 | 2020-07-08 | Zymogenetics Inc | Composiciones y métodos para modular respuestas inmunitarias |
JP2009538120A (ja) | 2006-04-13 | 2009-11-05 | ザイモジェネティクス, インコーポレイテッド | 四量体化ポリペプチドおよび使用方法 |
CA2648925A1 (en) | 2006-04-13 | 2007-10-25 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
US20090318376A1 (en) | 2006-06-15 | 2009-12-24 | Korea Research Institute Of Bioscience And Biotechnology | High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby |
WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
CN101541834A (zh) | 2006-10-06 | 2009-09-23 | 武田药品工业株式会社 | 癌症的预防和/或治疗剂 |
CA2694990A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
MX364200B (es) | 2008-04-09 | 2019-04-16 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
EP2370813A4 (en) | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
MA33122B1 (fr) | 2009-02-17 | 2012-03-01 | Ucb Pharma Sa | Molecules d'anticorps ayant une specificite pour ox40 humain |
US8431530B2 (en) | 2009-06-12 | 2013-04-30 | Morehouse School Of Medicine | Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
WO2011109637A1 (en) | 2010-03-03 | 2011-09-09 | Koo Foundation Sun Yat-Sen Cancer Center | Methods for classifying and treating breast cancers |
NZ623807A (en) | 2010-04-13 | 2016-03-31 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
WO2012129488A2 (en) | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
WO2012156515A1 (en) | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
US20140141996A1 (en) | 2011-06-22 | 2014-05-22 | Oncocyte Corporation | Methods and Compositions for the Treatment and Diagnosis of Cancer |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US20140056890A1 (en) | 2012-06-06 | 2014-02-27 | Oncomed Pharmaceuticals, Inc. | Binding Agents That Modulate the Hippo Pathway and Uses Thereof |
CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
PL3021869T3 (pl) | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US9713364B2 (en) | 2014-02-14 | 2017-07-25 | Alyssa Ashley Simmons | Foot habiliment with easily interchangeable outer |
US20150346210A1 (en) * | 2014-05-30 | 2015-12-03 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
JO3664B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | أجسام مضادة لـ tigit |
EP3789399A1 (en) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
MA40662B1 (fr) | 2014-12-23 | 2020-12-31 | Bristol Myers Squibb Co | Anticorps contre tigit |
EP3978929A1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
EP3295951B1 (en) * | 2015-02-19 | 2020-04-22 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
EP3265486A4 (en) | 2015-03-06 | 2018-11-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
CN115925931A (zh) | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
JP6861418B2 (ja) | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体 |
CA2997179A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
AU2016322934A1 (en) | 2015-09-14 | 2018-04-12 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta |
KR20200087283A (ko) | 2015-09-25 | 2020-07-20 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
AU2016331052B2 (en) | 2015-10-01 | 2023-08-03 | Potenza Therapeutics, Inc. | Anti-TIGIT antigen-binding proteins and methods of use thereof |
BR112018008891A8 (pt) * | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
PT3394103T (pt) | 2015-12-22 | 2023-09-04 | Regeneron Pharma | Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro |
MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
US10421811B2 (en) | 2016-04-25 | 2019-09-24 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies |
WO2018017864A2 (en) | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
DK3347379T5 (da) * | 2016-08-17 | 2020-06-15 | Compugen Ltd | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf |
-
2018
- 2018-06-01 WO PCT/IB2018/000696 patent/WO2018220446A1/en active Application Filing
- 2018-06-01 AU AU2018276140A patent/AU2018276140A1/en active Pending
- 2018-06-01 EP EP18749490.1A patent/EP3630180A1/en active Pending
- 2018-06-01 KR KR1020197037964A patent/KR20200021474A/ko active Search and Examination
- 2018-06-01 CN CN201880043405.XA patent/CN110799213A/zh active Pending
- 2018-06-01 MX MX2019014265A patent/MX2019014265A/es unknown
- 2018-06-01 CA CA3064331A patent/CA3064331A1/en active Pending
- 2018-06-01 JP JP2019565817A patent/JP7348072B2/ja active Active
- 2018-06-01 BR BR112019025035-2A patent/BR112019025035A2/pt unknown
- 2018-06-01 US US15/996,369 patent/US11225523B2/en active Active
- 2018-06-01 SG SG10202111336RA patent/SG10202111336RA/en unknown
-
2019
- 2019-11-28 IL IL271011A patent/IL271011A/en unknown
- 2019-11-29 CL CL2019003509A patent/CL2019003509A1/es unknown
-
2021
- 2021-12-07 US US17/544,852 patent/US20230070685A1/en active Pending
-
2023
- 2023-05-31 JP JP2023090131A patent/JP2023123462A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3064331A1 (en) | 2018-12-06 |
CN110799213A (zh) | 2020-02-14 |
AU2018276140A1 (en) | 2019-12-19 |
JP2020521778A (ja) | 2020-07-27 |
WO2018220446A1 (en) | 2018-12-06 |
CL2019003509A1 (es) | 2020-10-02 |
IL271011A (en) | 2020-01-30 |
US11225523B2 (en) | 2022-01-18 |
EP3630180A1 (en) | 2020-04-08 |
JP7348072B2 (ja) | 2023-09-20 |
BR112019025035A2 (pt) | 2020-06-30 |
JP2023123462A (ja) | 2023-09-05 |
SG10202111336RA (en) | 2021-11-29 |
US20190010246A1 (en) | 2019-01-10 |
WO2018220446A9 (en) | 2019-08-22 |
KR20200021474A (ko) | 2020-02-28 |
US20230070685A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019014265A (es) | Tratamientos conjuntos triples con anticuerpos. | |
EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
SG10201900571YA (en) | Anti-pd-1 antibodies | |
MX2020002289A (es) | Anticuerpos anti-alfa-sinucleina y metodos de uso. | |
MX2017000419A (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
MX2017012113A (es) | Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
MX2019003338A (es) | Tratamiento de cefalea en racimos. | |
DOP2019000064A (es) | Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
MX2019010797A (es) | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. | |
MX2016011809A (es) | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos. | |
MX2018008008A (es) | Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. | |
MX2021010119A (es) | Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1. | |
MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |